Table 1:

Baseline Characteristics

	Cohort A1 8Gy x1 +Durva (N=14)	Cohort A2 5Gy x5 +Durva (N=10)	Cohort C1 8Gy x1 +Durva/Treme (N=19)	Cohort C2 5Gy × 5 +Durva/Trem (N=16)
Age
Median	62.0	61.5	60.0	60.5
Range	43–80	48–77	43–85	44–79
Sex -- no. (%)
Female	7 (50)	5 (50)	9 (47)	1 (6)
Male	7 (50)	5 (50)	10 (53)	15 (94)
Ethnicity -- no.(%)
Asian	1 (7)	0 (0)	0 (0)	0 (0)
Black	2 (14)	0 (0)	3 (16)	4 (25)
White	11 (79)	10 (100)	16 (84)	12 (75)
ECOG -- no/ (%)
0	5 (36)	2 (20)	6 (32)	10 (63)
1	9 (64)	8 (80)	13 (68)	6 (38)
Pancreatic tumor location at diagnosis -- no. (%)
Head	4 (29)	3 (30)	13 (68)	9 (58)
Body	6 (43)	3 (30)	2 (11)	5 (31)
Tail	4 (29)	4(40)	4 (21)	1 (6)
Unknown	0 (0)	0(0)	0 (0)	1 (6)
Metastasis at diagnosis -- no. (%)	12 (86)	8 (80)	12 (63)	13 (81)
Previous therapy -- no. (%)
Radiation therapy	0 (0)	0 (0)	8 (42)	1 (6)
Chemotherapy	14 (100)	10 (100)	19 (100)	16 (100)
Whipple procedure	2 (14)	2 (20)	6 (32)	3 (19)
Biliary stent	0 (0)	0 (0)	1 (5)	1 (6)
Previous chemotherapy -- no (%)
1 line	4 (29)	2 (20)	3 (16)	6 (38)
2 lines	4 (29)	4 (40)	6 (32)	2 (13)
≥3 lines	6 (43)	4 (40)	10 (53)	8 (50)
Site of disease at enrollment -- no. (%)
Pancreas	14 (86)	8 (80)	14 (58)	13 (75)
Surgical bed	2 (14)	2 (20)	3 (16)	1 (6)
Liver	9 (64)	4 (40)	7 (37)	10 (63)
Lung	3 (21)	2 (20)	3 (16)	5 (31)
Peritoneum	1 (7)	1 (10)	3 (16)	2 (13)
No. of metastatic sites at enrollment -- no. (%)
1	6 (43)	7 (70)	9 (47)	10 (63)
2	5 (21)	0 (0)	2 (11)	4 (25)
3	1 (7)	1 (10)	2 (11)	0 (0)
Level of CA 19-9 at enrollment-- no. (%)
Normal (0–34.9 U/ml)	0 (0)	2 (20)	2 (11)	2 (13)
ULN to ≤59× ULN	3 (21)	5 (50)	10 (53)	5 (31)
>59× ULN	11 (79)	3 (30)	7 (37)	10 (63)
CA 19-9 (U/ml) at enrollment
Median	5067.5	853.1	1349.0	5880.5
Range	175.5–97560	29.3–57040	0.6–536100	2.3–49800

Abbreviation: Durva: Durvalumab; Treme: Tremelimumab; ECOG: Eastern Cooperative Oncology Group